Kari Laine1, Tuija Heikkinen, Ulla Ekblad, Pentti Kero. 1. Department of Pharmacology and Clinical Pharmacology, University of Turku and Turku University Central Hospital, Turku, Finland. karlai@utu.fi
Abstract
BACKGROUND:Selective serotonin reuptake inhibitors (SSRIs) have gained wide acceptance in the treatment of mental disorders in pregnant women, but there seems to be an increased risk for neonatal adaptation problems after exposure to SSRIs in late pregnancy. We aimed to investigate the perinatal sequelae of infants exposed to SSRIs during their fetal life and the relationship of these symptoms to the cord blood monoamine and prolactin concentrations. METHODS: We conducted a prospective, controlled, follow-up study with 20 mothers taking 20 to 40 mg/d of eithercitalopram or fluoxetinefor depression (n = 10) or panic disorder (n = 10) and their infants and 20 matched controls not receiving psychotropic medication for confounding obstetric characteristics. Maternal cord blood and infant citalopram, fluoxetine, and norfluoxetine, cord blood monoamine and metabolite, and prolactin concentrations were measured. The newborns underwent standard clinical examination and specific assessment of serotonergic symptoms during the first 4 days of life and at the ages of 2 weeks and 2 months. RESULTS: There was a statistically significant (P =.008, V = 15, n = 20 for both groups), 4-fold difference in the serotonergic symptom score during the first 4 days of life between the SSRI group and the control group. The SSRI-exposed infants had significantly lower cord blood 5-hydroxyindoleacetic acid (5-HIAA) concentrations (P =.02, t31 = 2.57) compared with the control group. A significant inverse correlation (rs = -0.66, P =.007, n = 15) was seen between the serotonergic symptom score and the umbilical vein 5-HIAA concentrations in the SSRI-exposed but not the control infants. CONCLUSIONS: Infants exposed to SSRIs during late pregnancy are at increased risk for serotonergic central nervous system adverse effects, and the severity of these symptoms is significantly related to cord blood 5-HIAA levels.
RCT Entities:
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) have gained wide acceptance in the treatment of mental disorders in pregnant women, but there seems to be an increased risk for neonatal adaptation problems after exposure to SSRIs in late pregnancy. We aimed to investigate the perinatal sequelae of infants exposed to SSRIs during their fetal life and the relationship of these symptoms to the cord blood monoamine and prolactin concentrations. METHODS: We conducted a prospective, controlled, follow-up study with 20 mothers taking 20 to 40 mg/d of either citalopram or fluoxetine for depression (n = 10) or panic disorder (n = 10) and their infants and 20 matched controls not receiving psychotropic medication for confounding obstetric characteristics. Maternal cord blood and infantcitalopram, fluoxetine, and norfluoxetine, cord blood monoamine and metabolite, and prolactin concentrations were measured. The newborns underwent standard clinical examination and specific assessment of serotonergic symptoms during the first 4 days of life and at the ages of 2 weeks and 2 months. RESULTS: There was a statistically significant (P =.008, V = 15, n = 20 for both groups), 4-fold difference in the serotonergic symptom score during the first 4 days of life between the SSRI group and the control group. The SSRI-exposed infants had significantly lower cord blood 5-hydroxyindoleacetic acid (5-HIAA) concentrations (P =.02, t31 = 2.57) compared with the control group. A significant inverse correlation (rs = -0.66, P =.007, n = 15) was seen between the serotonergic symptom score and the umbilical vein 5-HIAA concentrations in the SSRI-exposed but not the control infants. CONCLUSIONS:Infants exposed to SSRIs during late pregnancy are at increased risk for serotonergic central nervous system adverse effects, and the severity of these symptoms is significantly related to cord blood 5-HIAA levels.
Authors: L E Ross; S Grigoriadis; L Mamisashvili; G Koren; M Steiner; C-L Dennis; A Cheung; P Mousmanis Journal: Int J Methods Psychiatr Res Date: 2011-12 Impact factor: 4.035
Authors: Regina C Casper; Allyson A Gilles; Barry E Fleisher; Joan Baran; Gregory Enns; Laura C Lazzeroni Journal: Psychopharmacology (Berl) Date: 2011-04-16 Impact factor: 4.530
Authors: John Kim; K Wayne Riggs; Shaila Misri; Nancy Kent; Tim F Oberlander; Ruth E Grunau; Colleen Fitzgerald; Dan W Rurak Journal: Br J Clin Pharmacol Date: 2006-02 Impact factor: 4.335
Authors: Sarah R Delaney; Paul R V Malik; Cristiana Stefan; Andrea N Edginton; David A Colantonio; Shinya Ito Journal: Clin Pharmacokinet Date: 2018-12 Impact factor: 6.447
Authors: Amy L Salisbury; George D Papandonatos; Laura R Stroud; Alicia K Smith; Patricia A Brennan Journal: Dev Psychobiol Date: 2020-03-13 Impact factor: 3.038